← Leaderboards
Ehsan Yazdi
Nomocan Pharmaceuticals, Llc
$854,125
Attributed
$854,125
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $499.2K · FY2023–25$500K$375K$250K$125K$0
'23
'24
'25
Funding mix
By agency
NIH$854,125 · 2
By mechanism
N43$854,125 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Survival Rate”
- Michael E. Roth · Public Health Institute$8,201,777
- Stuart Marcus · Sonalasense Inc$3,968,035
- Martin Pule · University College London$3,627,871
- Stephanie Ham · Continuity Biosciences, Llc$2,995,581
- Pamela Lutsey · University Of Minnesota$2,984,967
- Eric Holbrook · Miravista Diagnostics, Llc$2,971,862
Research focus
Survival RateMdm2 GenePancreasTargeted TreatmentIn VitroBindingIn VivoMouse ModelVariantImmunogenicityMonoclonal AntibodiesCombined Modality TherapyCancer TherapyDrug CandidateChemotherapyCessation Of LifeCancer EtiologyAntibody-Drug ConjugatesHumanized AntibodyCellsGenerationsHumanized Monoclonal AntibodiesFutureCell Membrane
Grant awards (2)
NOMOCAN PHASE I - DEVELOPMENT OF THERAPEUTIC OR PREVENTATIVE TECHNOLOGIES FOR TREATMENT OR PREVENTION OF PEDIATRIC CANCERS AND/OR RARE CANCERS SBIR CONTRACTPHASE I - DEVELOPMENT OF THERAPEUTIC OR PRE$499,166
N43 · FY2025 · CA · contact PI
PURPOSE OF THIS MODIFICATION IS TO EXERCISE THE I-CORP OPTION$354,959
N43 · FY2023 · CA · contact PI